At­las cre­ates sec­ond op­por­tu­ni­ty fund with $300M; BioN­Tech's col­orec­tal can­cer vac­cine starts PhII tri­al

Life sci­ence VC At­las Ven­ture closed its sec­ond Op­por­tu­ni­ty Fund with $300 mil­lion. Known as AVOF II, the fund will en­able At­las to con­tin­ue back­ing its port­fo­lio com­pa­nies, ac­cord­ing to a com­pa­ny state­ment.

“We are de­light­ed to re­ceive sup­port from both our long­stand­ing LP base and new in­vestors in AVOF II, for our mis­sion of build­ing and scal­ing biotech com­pa­nies that can bring nov­el med­i­cines to pa­tients,” said At­las part­ner David Grayzel in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER